Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
NCT06355609
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
sunvozertinib in combination with Anlotinib
Sponsor
Hunan Province Tumor Hospital